Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the licensing agreement, Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90, an O-GlcNAcase inhibitor, in progressive supranuclear palsy (PSP), an orphan, tau-related disease with a high unmet medical need.
Brand Name : ASN90
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 22, 2023
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Findings published demonstrated increased survival in preclinical model of Alzheimer's disease after administration of clinical molecule ASN90, an O–GlcNAcase inhibitor, as well as significant motor impairment and astrogliosis effect in a Parkinson's m...
Brand Name : ASN90
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 01, 2022
Lead Product(s) : ASN90
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?